Savara Inc. (SVRA) |
| 6.03 -0.26 (-4.13%) 07-10 16:00 |
| Open: | 6.29 |
| High: | 6.29 |
| Low: | 5.93 |
| Volume: | 1,720,421 |
| Market Cap: | 1,236(M) |
| PE Ratio: | -10.77 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 7.56 |
| Resistance 1: | 6.47 |
| Pivot price: | 6.02 |
| Support 1: | 5.40 |
| Support 2: | 4.73 |
| 52w High: | 7.005 |
| 52w Low: | 2.25 |
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Financials
| EPS | -0.560 |
| Book Value | 0.690 |
| PEG Ratio | 0.00 |
| Gross Profit | -0.397 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -40.5 |
| Return on Equity (ttm) | -79.9 |
Company news
Sat, 04 Jul 2026
Enterprise value to EBIT forward of Savara, Inc. – NASDAQ:SVRA - TradingView
Sun, 28 Jun 2026
Levi & Korsinsky Notifies Savara Inc. (SVRA) Investors - Lead Plaintiff Deadline on November 7, 2025 - The National Law Review
Fri, 26 Jun 2026
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
Mon, 22 Jun 2026
Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4 - Stock Titan
Mon, 08 Jun 2026
Savara (SVRA) Announces Leadership Changes in Finance Department - GuruFocus
Mon, 08 Jun 2026
Savara Announces Chief Financial and Administrative Officer Transition - Business Wire
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
